Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.30 +0.17%

+$0.02 today

Market cap
$546.27M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.87M

Average 0.88M

CLYM EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Climb Bio, Inc.NASDAQ: CLYM

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$13.68M, compared with -$20.78M a year earlier. Trailing-twelve-month EBITDA was -$52.66M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -96.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.68M+21.7% QoQ
Last fiscal yearDec 2025
-$59.75M-96.8% YoY
LTMMar 2026
-$52.66M+43.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.2%+100.0%+65.8 pp
1 year-96.8%+100.0%+196.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(59.75M) USD
Year-over-year change
-96.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CLYM compares with its peers on the latest reported figures

  • CLYM's LTM Mar 2026 EBITDA of -$52.66M is the highest of the 5 companies compared; the peer median is -$164.08M.
  • Its year-over-year change of +43.4% is the highest of 5, against a peer median of -73.1%.
CLYM Competitors Peer median
EBITDA for CLYM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLYMClimb Bio, Inc.LTM Mar 2026-$52.66M +43.4%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.03M -325.2%——
UPBUpstream Bio, Inc.LTM Mar 2026-$156.57M -98.0%—4713.1%
CABACabaletta Bio, Inc.LTM Mar 2026-$171.58M -48.1%——
TRAXFirst Tracks Biotherapeutics IncFY2025-$178.45M +0.1%——
Peer median (excluding CLYM) -$164.08M-73.1%—4713.1%

Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000097K
Gross Profit0000(97K)
Gross Margin—————
Research & Development23.32M26.21M15.41M14.34M46.62M
Selling, General & Admin12.35M18.92M24.86M16.03M21.17M
Operating Expenses35.67M45.14M40.28M82.02M67.79M
Depreciation & Amortization000097K
EBITDA(47.48M)(45.24M)(35.12M)(30.36M)(59.75M)
EBITDA Margin—————
Operating Income(35.67M)(45.14M)(40.28M)(82.02M)(67.88M)
Operating Margin—————
Interest Income01.38M4.62M8.13M8.32M
Interest Expense00000
Other Income / Expenses(11.81M)(109K)5.16M8.12M8.03M
Income Before Tax(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(47.48M)(45.24M)(35.12M)(73.9M)(59.85M)
Net Margin—————
EPS (Basic)(4.24)(1.72)(1.30)(1.53)(0.88)
EPS (Diluted)(4.24)(1.72)(1.30)(1.53)(0.88)
Weighted Avg Shares12.26M26.31M26.99M48.16M67.81M
Weighted Avg Shares (Diluted)12.26M26.31M26.99M48.16M67.81M

Climb Bio, Inc.

NASDAQ:CLYM

Intrinsic Alpha fair value

Locked

Current Price

$9.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.